Skip to main content
Top
Published in: Current Infectious Disease Reports 11/2019

01-11-2019 | Vulvovaginal Candidiasis | Female Genital Tract Infections (J Sobel, Section Editor)

Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure

Authors: Asmita Shukla, J. D. Sobel

Published in: Current Infectious Disease Reports | Issue 11/2019

Login to get access

Abstract

Purpose of Review

Goal was to review epidemiology, pathophysiology, and prevention of post-antibiotic Candida vulvovaginitis (VVC).

Recent Findings

Antibacterial therapy, whether systemic or locally applied to the vagina, represents the single most frequent and predictable cause or triggering mechanism of symptomatic vulvovaginal candidiasis (VVC). Such initiating mechanisms may precipitate sporadic or recurrent episodes of VVC. In spite of this widely recognized association, the exact mechanism whereby antibiotics of all classes cause acute exacerbation of symptomatic vaginal disease remains largely unstudied and therefore largely unknown. Pathophysiology is hypothesized to be reduction or alteration of vaginal microbiome restraints of yeast colonization, proliferation, and expression of virulence characteristics.

Summary

The predictable link between antibiotic use and post-antibiotic VVC affords practitioners an opportunity for timely intervention using selective, convenient antimycotics usually drugs but possibly probiotic measures. Indications and limitation of these steps are discussed.
Literature
1.
go back to reference Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214:15–21.CrossRef Sobel JD. Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2016;214:15–21.CrossRef
2.
go back to reference Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis. A. Systematic review. Lancet Infect Dis. 2018;18:339–47.CrossRef Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis. A. Systematic review. Lancet Infect Dis. 2018;18:339–47.CrossRef
3.
go back to reference Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant, Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.CrossRef Marchaim D, Lemanek L, Bheemreddy S, Kaye KS, Sobel JD. Fluconazole-resistant, Candida albicans vulvovaginitis. Obstet Gynecol. 2012;120(6):1407–14.CrossRef
4.
go back to reference lj C. Vaginal moniliasis after tetracycline therapy: the effects of amphotericin B. Am J Obstet Gynecol. 1964;90:374–8. lj C. Vaginal moniliasis after tetracycline therapy: the effects of amphotericin B. Am J Obstet Gynecol. 1964;90:374–8.
5.
go back to reference Oriel JD, Waterworth PM. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol. 1975;28:403–6.CrossRef Oriel JD, Waterworth PM. Effects of minocycline and tetracycline on the vaginal yeast flora. J Clin Pathol. 1975;28:403–6.CrossRef
6.
go back to reference Iravani A, Richard GA. Amoxicillin-clavulanic acid versus Cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrob Ag Chemo. 1986;29:107–9.CrossRef Iravani A, Richard GA. Amoxicillin-clavulanic acid versus Cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrob Ag Chemo. 1986;29:107–9.CrossRef
7.
go back to reference Bluestein D, Rutledge C, Lumsden L. Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV). Fam Pract Res J. 1991;11:319–26.PubMed Bluestein D, Rutledge C, Lumsden L. Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV). Fam Pract Res J. 1991;11:319–26.PubMed
8.
go back to reference MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick AD, McDevitt DG. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med. 1993;86:419–24.PubMed MacDonald TM, Beardon PH, McGilchrist MM, Duncan ID, McKendrick AD, McDevitt DG. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q J Med. 1993;86:419–24.PubMed
9.
go back to reference Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7:182–7.CrossRef Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7:182–7.CrossRef
10.
go back to reference Glover DD, Larsen B. Relationship of fungal vaginitis therapy to prior antibiotic exposure. Infect Dis Obstet Gyn. 2003;11:157–60.CrossRef Glover DD, Larsen B. Relationship of fungal vaginitis therapy to prior antibiotic exposure. Infect Dis Obstet Gyn. 2003;11:157–60.CrossRef
11.
go back to reference Spinillo A, Capuzzo E, Acciano A, Santolo AD, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol. 1999;180:14–7.CrossRef Spinillo A, Capuzzo E, Acciano A, Santolo AD, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol. 1999;180:14–7.CrossRef
12.
go back to reference Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Interna J Antimicrob Ag. 2002;20:297–300.CrossRef Menday AP. Symptomatic vaginal candidiasis after pivmecillinam and norfloxacin treatment of acute uncomplicated lower urinary tract infection. Interna J Antimicrob Ag. 2002;20:297–300.CrossRef
13.
go back to reference Pirotta MV, Gunn JM, Chondros P. “Not thrush again!” Women’s experience of post-antibiotic vulvovaginitis. General Practice In Action. 2003;179:43–6. Pirotta MV, Gunn JM, Chondros P. “Not thrush again!” Women’s experience of post-antibiotic vulvovaginitis. General Practice In Action. 2003;179:43–6.
14.
go back to reference Pirotta M, Gunn J, Chondros P, Grover S, O’Malley P, Hurley S, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ. 2004;27:1–5.CrossRef Pirotta M, Gunn J, Chondros P, Grover S, O’Malley P, Hurley S, et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomized controlled trial. BMJ. 2004;27:1–5.CrossRef
15.
go back to reference Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Micro. 2006;44:3213–7.CrossRef Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Micro. 2006;44:3213–7.CrossRef
16.
go back to reference Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses. 2006;49:523–4.CrossRef Tabrizi SN, Pirotta MV, Rudland E, Garland SM. Detection of Candida species by PCR in self-collected vaginal swabs of women after taking antibiotics. Mycoses. 2006;49:523–4.CrossRef
17.
go back to reference Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med. 2008;21:261–8.CrossRef Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med. 2008;21:261–8.CrossRef
18.
go back to reference Woods JW, Manning IH Jr, Patterson CN. Monilial infections complicating the therapeutic use of antibiotics. J Am Med Assoc. 1951;145(4):207–11.CrossRef Woods JW, Manning IH Jr, Patterson CN. Monilial infections complicating the therapeutic use of antibiotics. J Am Med Assoc. 1951;145(4):207–11.CrossRef
19.
go back to reference Miller CP. New problems in the treatment of infectious diseases. Ann Intern Med. 1951;35(4):763–70.CrossRef Miller CP. New problems in the treatment of infectious diseases. Ann Intern Med. 1951;35(4):763–70.CrossRef
20.
go back to reference Waterworth PM. The effect of minocycline on Candida albicans. J Clin Pathol. 1974;27:269–72.CrossRef Waterworth PM. The effect of minocycline on Candida albicans. J Clin Pathol. 1974;27:269–72.CrossRef
21.
go back to reference Glover DD, Larsen B. Longitudinal investigation of Candida vaginitis in pregnancy: role of superimposed antibiotic use. Obstet Gynecol. 1998;91:115–8.CrossRef Glover DD, Larsen B. Longitudinal investigation of Candida vaginitis in pregnancy: role of superimposed antibiotic use. Obstet Gynecol. 1998;91:115–8.CrossRef
22.
go back to reference McVay LV Jr, Srunt DH. A study of moniliasis in aureomycin therapy. Proc Soc Exp Biol Med. 1951;78(3):759–61.CrossRef McVay LV Jr, Srunt DH. A study of moniliasis in aureomycin therapy. Proc Soc Exp Biol Med. 1951;78(3):759–61.CrossRef
23.
go back to reference Moore M. In vivo and in vitro effect of aureomycin hydrochloride on Syringospora (Monilia, Candida) albicans. J Lab Clin Med. 1951;37(5):703–12.PubMed Moore M. In vivo and in vitro effect of aureomycin hydrochloride on Syringospora (Monilia, Candida) albicans. J Lab Clin Med. 1951;37(5):703–12.PubMed
24.
go back to reference Huppert M, MacPherson DA, Cazin J. Pathogenesis of Candida Albicans infection following antibiotic therapy. Department of Bacteriology and Immunology, University of North Carolina School of Medicine. 1952;65:171–6. Huppert M, MacPherson DA, Cazin J. Pathogenesis of Candida Albicans infection following antibiotic therapy. Department of Bacteriology and Immunology, University of North Carolina School of Medicine. 1952;65:171–6.
26.
go back to reference Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub A. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gyn. 2019;220:324–36.CrossRef Greenbaum S, Greenbaum G, Moran-Gilad J, Weintraub A. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gyn. 2019;220:324–36.CrossRef
26.
go back to reference Agnew KJ, Hillier SL. The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis. 1995 Sep-Oct;22(5):269–73.CrossRef Agnew KJ, Hillier SL. The effect of treatment regimens for vaginitis and cervicitis on vaginal colonization by lactobacilli. Sex Transm Dis. 1995 Sep-Oct;22(5):269–73.CrossRef
27.
go back to reference Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol. 1996;34(10):2497–9.PubMedPubMedCentral Sobel JD, Chaim W. Vaginal microbiology of women with acute recurrent vulvovaginal candidiasis. J Clin Microbiol. 1996;34(10):2497–9.PubMedPubMedCentral
28.
go back to reference St H, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infection. J Infect Dis. 1996;174:1058–63.CrossRef St H, Hillier SL, Benedetti J, et al. Hydrogen peroxide-producing lactobacilli and acquisition of vaginal infection. J Infect Dis. 1996;174:1058–63.CrossRef
29.
go back to reference Chetwin E, Manhanzva MT, Abrahams AG, Froissart R, Gamieldien H, Jaspan H, et al. Antimicrobial and inflammatory properties of South African clinical Lactobacillus isolates and vaginal probiotics. Sci Rep. 2019;9:1917.CrossRef Chetwin E, Manhanzva MT, Abrahams AG, Froissart R, Gamieldien H, Jaspan H, et al. Antimicrobial and inflammatory properties of South African clinical Lactobacillus isolates and vaginal probiotics. Sci Rep. 2019;9:1917.CrossRef
30.
go back to reference Nichols RG, Peters JM, Patterson AD. Interplay between the host, the human microbiome, and drug metabolism. Hum Genomics. 2019;13(1):27.CrossRef Nichols RG, Peters JM, Patterson AD. Interplay between the host, the human microbiome, and drug metabolism. Hum Genomics. 2019;13(1):27.CrossRef
31.
go back to reference Swidsinski A, Guschin A, Tang Q, Dörffel Y, Verstraelen H, Tertychnyy A, et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am J Obstet Gynecol. 2019 Jan;220(1):91.e1–8.CrossRef Swidsinski A, Guschin A, Tang Q, Dörffel Y, Verstraelen H, Tertychnyy A, et al. Vulvovaginal candidiasis: histologic lesions are primarily polymicrobial and invasive and do not contain biofilms. Am J Obstet Gynecol. 2019 Jan;220(1):91.e1–8.CrossRef
Metadata
Title
Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure
Authors
Asmita Shukla
J. D. Sobel
Publication date
01-11-2019
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 11/2019
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-019-0700-y

Other articles of this Issue 11/2019

Current Infectious Disease Reports 11/2019 Go to the issue

Technology and Infectious Disease (C Hebert, Section Editor)

The Current and Future Use of Telemedicine in Infectious Diseases Practice

Tropical, Travel and Emerging Infections (L Chen and A Boggild, Section Editors)

Yellow Fever in Travelers

Tropical, Travel and Emerging Infections (L Chen and A Boggild, Section Editors)

Utility of 8-Aminoquinolines in Malaria Prophylaxis in Travelers

Transplant and Oncology (M Ison, N Theodoropoulos, and S Pergam, Section Editors)

CMV Prevention and Treatment in Transplantation: What’s New in 2019

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.